No Data
Xiamen Amoytop Biotech Gets Clinical Trial Approval for Peijin Drug
Xiamen Amoytop Biotech (688278.SH): The new indication for Peijin has received a drug clinical trial approval notice.
On January 6th, GLB announced that Xiamen Amoytop Biotech (688278.SH) recently received the approval from the National Medical Products Administration for a new indication for its product Peijin (generic name: Tuopeifeisiting injection) "suitable for reducing the incidence of preeclampsia", along with the "Drug Clinical Trial Approval Notification". Peijin utilizes a 40kD Y-shaped branched polyethylene glycol (PEG) molecule to modify human granulocyte stimulating factor, stimulating hematopoietic stem cells in the bone marrow to differentiate into granulocytes, promoting granulocyte proliferation, maturation, and release, thus restoring the count of neutrophils in peripheral blood to decrease the risk of infection following chemotherapy in cancer patients.
Sinolink: Major policies have been released, innovation remains the most important direction. The pharmaceutical and healthcare Industry has entered a performance window, focusing on reversal expectations.
The market has entered the window period for annual and quarterly reports, and it is recommended to actively pay attention to the fundamental Bearish clearance of left-side symbols (such as some Medical Devices, Traditional Chinese Medicine, pharmacies, chain Medical, CXO, etc.) and the implementation of centralized procurement policies.
Are Investors Undervaluing Xiamen Amoytop Biotech Co., Ltd. (SHSE:688278) By 24%?
Sinolink: The end of year centralized purchasing expectations are gradually being cleared, and the pharmaceutical sector行情 is expected to gradually start.
The pharmaceutical Sector is currently in a process of a triple reversal in performance, policies, and funding, with full confidence in the recovery of revenue profit growth and market resurgence of listed companies in the Sector by 2025.
Sinolink Securities: The favorable wind of medical policies arrives first, followed by innovation going abroad and performance reversal.
In 2025, Sinolink believes that the core investment opportunities in the pharmaceutical Sector will revolve around three main logics: 1) innovation going abroad; 2) demand recovery; 3) reversal of policy expectations.
Here's Why We Think Xiamen Amoytop Biotech (SHSE:688278) Might Deserve Your Attention Today
No Data
